AR122771A2 - Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huésped - Google Patents
Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huéspedInfo
- Publication number
- AR122771A2 AR122771A2 ARP210101787A ARP210101787A AR122771A2 AR 122771 A2 AR122771 A2 AR 122771A2 AR P210101787 A ARP210101787 A AR P210101787A AR P210101787 A ARP210101787 A AR P210101787A AR 122771 A2 AR122771 A2 AR 122771A2
- Authority
- AR
- Argentina
- Prior art keywords
- nucleic acid
- pharmaceutical composition
- host cell
- conjugated
- antibodies
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Anticuerpo anti-CLDN6 que comprende una cadena pesada de anticuerpo y una cadena ligera de anticuerpo, en el que la cadena pesada de anticuerpo comprende al menos una de las secuencias de CDR de la secuencia de cadena pesada de anticuerpo de SEQ ID Nº 36 y la cadena ligera de anticuerpo comprende al menos una de las secuencias de CDR de una secuencia de cadena ligera de anticuerpo seleccionada de las SEQ ID Nº 35, 54 y 55; conjugado; composición farmacéutica; ácido nucleico; y célula huésped.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11004004 | 2011-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR122771A2 true AR122771A2 (es) | 2022-10-05 |
Family
ID=47176322
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120101613A AR086306A1 (es) | 2011-05-13 | 2012-05-08 | Anticuerpos para el tratamiento del cancer |
ARP210101787A AR122771A2 (es) | 2011-05-13 | 2021-06-28 | Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huésped |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120101613A AR086306A1 (es) | 2011-05-13 | 2012-05-08 | Anticuerpos para el tratamiento del cancer |
Country Status (29)
Country | Link |
---|---|
US (5) | US9321842B2 (es) |
EP (3) | EP2707390B1 (es) |
JP (3) | JP6276176B2 (es) |
KR (3) | KR102430870B1 (es) |
CN (3) | CN103748112B (es) |
AR (2) | AR086306A1 (es) |
AU (4) | AU2012258087B2 (es) |
BR (1) | BR112013029212B1 (es) |
CA (1) | CA2832174C (es) |
CY (2) | CY1118608T1 (es) |
DK (2) | DK3026064T3 (es) |
ES (1) | ES2565063T3 (es) |
HK (1) | HK1195320A1 (es) |
HR (2) | HRP20160212T1 (es) |
HU (1) | HUE028603T2 (es) |
IL (1) | IL228738B (es) |
LT (1) | LT3026064T (es) |
ME (1) | ME02369B (es) |
MX (4) | MX341147B (es) |
NZ (3) | NZ741567A (es) |
PL (2) | PL2707390T3 (es) |
RS (2) | RS54627B1 (es) |
RU (1) | RU2676731C2 (es) |
SG (1) | SG193551A1 (es) |
SI (2) | SI2707390T1 (es) |
SM (1) | SMT201600064B (es) |
UA (2) | UA127584C2 (es) |
WO (1) | WO2012156018A1 (es) |
ZA (1) | ZA201307102B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2370554B1 (en) | 2008-11-28 | 2019-05-15 | Corbion Biotech, Inc. | Manufacturing of tailored oils in recombinant heterotrophic microorganisms |
KR102340685B1 (ko) | 2009-02-20 | 2021-12-17 | 가니메드 파마슈티칼스 게엠베하 | 암의 진단 및 치료를 위한 방법 및 조성물 |
BR112012011143B1 (pt) | 2009-11-11 | 2020-05-19 | Ganymed Pharmaceuticals Ag | "anticorpos específicos para claudina 6 (cldn6)". |
EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
MX341147B (es) | 2011-05-13 | 2016-08-09 | Ganymed Pharmaceuticals Ag | Anticuerpos para el tratamiento del cáncer que expresa cldn6. |
CN104662044B (zh) | 2012-08-24 | 2018-10-30 | 加利福尼亚大学董事会 | 用于治疗ror1癌症并抑制转移的抗体和疫苗 |
WO2015014376A1 (en) * | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
PE20160870A1 (es) * | 2013-11-06 | 2016-09-09 | Abbvie Stemcentrx Llc | Anticuerpos anti-claudina novedosos y metodos de uso |
CN113278076A (zh) | 2013-11-11 | 2021-08-20 | 中外制药株式会社 | 含有改变了抗体可变区的抗原结合分子 |
EP3095462B1 (en) * | 2014-01-15 | 2019-08-14 | Order-Made Medical Research Inc. | Therapeutic pharmaceutical composition employing anti-slc6a6 antibody |
PT3514172T (pt) * | 2014-04-01 | 2020-04-21 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Imunorrecetores específicos de claudina-6 e epítopos de células t |
US11154615B2 (en) | 2014-11-11 | 2021-10-26 | Chugai Seiyaku Kabushiki Kaisha | Library of antigen-binding molecules including modified antibody variable region |
CA2966753A1 (en) | 2014-11-17 | 2016-05-26 | Arno Therapeutics, Inc. | Onapristone extended-release compositions and methods |
CN106146666B (zh) * | 2015-03-26 | 2019-09-06 | 科济生物医药(上海)有限公司 | 靶向cldn6的免疫效应细胞及其制备方法和应用 |
CN105504051B (zh) * | 2015-12-17 | 2019-08-30 | 北京天成新脉生物技术有限公司 | 狂犬病毒核蛋白单克隆抗体及其应用 |
MX2018016330A (es) | 2016-06-27 | 2020-02-17 | Univ California | Combinaciones para tratamiento del cáncer. |
US20180148471A1 (en) | 2016-11-30 | 2018-05-31 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
TW201827077A (zh) * | 2016-12-28 | 2018-08-01 | 美商建南德克公司 | 晚期her2表現癌症之治療 |
WO2019048040A1 (en) * | 2017-09-06 | 2019-03-14 | Ganymed Pharmaceuticals Gmbh | ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER |
GB202103867D0 (en) * | 2017-09-18 | 2021-05-05 | Univ California | Claudin6 antibodies and methods of treating cancer |
US11628223B2 (en) | 2017-09-29 | 2023-04-18 | Daiichi Sankyo Company, Limited | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines |
JP7357616B2 (ja) | 2017-12-05 | 2023-10-06 | 中外製薬株式会社 | Cd3およびcd137に結合する改変された抗体可変領域を含む抗原結合分子 |
WO2019135404A1 (en) * | 2018-01-05 | 2019-07-11 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
KR102340989B1 (ko) * | 2018-03-28 | 2021-12-20 | 에이비온 주식회사 | 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도 |
CN113767113A (zh) * | 2019-02-15 | 2021-12-07 | 因特格尔莫来库乐有限公司 | 密封蛋白6抗体及其用途 |
JP2022520632A (ja) | 2019-02-15 | 2022-03-31 | インテグラル・モレキュラー・インコーポレイテッド | 共通軽鎖を含む抗体及びその使用 |
MX2021011330A (es) * | 2019-03-20 | 2021-12-10 | Univ California | Anticuerpos de claudina-6 y conjugados de fármacos. |
EP3941944A4 (en) * | 2019-03-20 | 2022-11-30 | The Regents of the University of California | B-SPECIFIC CLAUDIN-6 ANTIBODIES |
CN113950485A (zh) | 2019-07-10 | 2022-01-18 | 中外制药株式会社 | 密蛋白-6结合分子及其用途 |
WO2021129927A1 (en) | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
CN111087465B (zh) * | 2019-12-24 | 2020-12-08 | 广州医科大学 | 一种针对密蛋白6的抗体偶联药物及应用 |
BR112022017305A2 (pt) | 2020-03-31 | 2022-10-11 | Chugai Pharmaceutical Co Ltd | Moléculas de ligação ao antígenos multiespecíficas que têm como alvo claudina-6 e usos das mesmas |
CA3199976A1 (en) * | 2020-11-06 | 2022-05-12 | Amgen Research (Munich) Gmbh | Polypeptide constructs selectively binding to cldn6 and cd3 |
IL305736A (en) | 2021-03-09 | 2023-11-01 | Xencor Inc | Heterodimeric antibodies that bind CD3 and CLDN6 |
US20230008868A1 (en) * | 2021-07-08 | 2023-01-12 | Nippon Telegraph And Telephone Corporation | User authentication device, user authentication method, and user authentication computer program |
JPWO2023053282A1 (es) | 2021-09-29 | 2023-04-06 | ||
CA3234897A1 (en) * | 2021-10-14 | 2023-04-20 | Kunle Odunsi | Compositions and methods for use of recombinant t cell receptors against claudin 6 |
AU2022405694A1 (en) | 2021-12-09 | 2024-07-04 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
WO2024046572A1 (en) | 2022-09-01 | 2024-03-07 | BioNTech SE | Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer |
WO2024088325A1 (zh) * | 2022-10-25 | 2024-05-02 | 科济生物医药(上海)有限公司 | 抗体及其应用 |
WO2024095964A1 (ja) * | 2022-10-31 | 2024-05-10 | アステラス製薬株式会社 | Toll様受容体7/8デュアルアゴニスト化合物を含む抗体薬物複合体 |
CN116064622B (zh) * | 2023-02-13 | 2023-10-13 | 优睿赛思(武汉)生物科技有限公司 | Claudin6-mCherry报告基因CHO-K1稳转细胞株制备及应用 |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946788A (en) | 1985-06-11 | 1990-08-07 | Ciba-Geigy Corporation | Purified immunoglobulin-related factor, novel monoclonal antibodies, hybridoma cell lines, processes and applications |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
GB9019812D0 (en) | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
US5830755A (en) | 1995-03-27 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | T-cell receptors and their use in therapeutic and diagnostic methods |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5677139A (en) | 1995-04-21 | 1997-10-14 | President And Fellows Of Harvard College | In vitro differentiation of CD34+ progenitor cells into T lymphocytes |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
WO2002000690A2 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
WO2000078961A1 (en) | 1999-06-23 | 2000-12-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2000012708A2 (en) | 1998-09-01 | 2000-03-09 | Genentech, Inc. | Further pro polypeptides and sequences thereof |
US5928631A (en) | 1997-06-09 | 1999-07-27 | The Procter & Gamble Company | Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins |
US20020127584A1 (en) | 1997-09-18 | 2002-09-12 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US5932445A (en) | 1997-11-07 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Signal peptide-containing proteins |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
EP1127119A1 (en) | 1998-11-03 | 2001-08-29 | Adherex Technologies, Inc. | Compounds and methods for modulating claudin-mediated functions |
EP1140970A4 (en) | 1998-12-17 | 2003-10-22 | Human Genome Sciences Inc | 47 HUMAN SECRETED PROTEINS |
WO2000050588A2 (en) | 1999-02-22 | 2000-08-31 | Incyte Pharmaceuticals, Inc. | Genes associated with diseases of the colon |
ES2287020T3 (es) | 1999-06-02 | 2007-12-16 | Genentech, Inc. | Procedimiento y composiciones para inhibir el crecimiento de celulas neoplasicas. |
EP1067182A3 (en) | 1999-07-08 | 2001-11-21 | Helix Research Institute | Secretory protein or membrane protein |
WO2001053312A1 (en) | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
WO2001051513A2 (en) | 2000-01-14 | 2001-07-19 | Corixa Corporation | Ovarian tumor-associated sequences |
KR101215789B1 (ko) | 2000-03-30 | 2012-12-26 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Rna 간섭의 rna 서열 특이적인 매개체 |
AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
EP1354040A2 (en) | 2000-07-20 | 2003-10-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
JP2004516013A (ja) | 2000-07-20 | 2004-06-03 | ジェネンテック・インコーポレーテッド | 血管形成に関連する障害を診断及び治療するための組成物と方法 |
EA013564B1 (ru) | 2000-08-03 | 2010-06-30 | Терапеутик Хьюман Поликлоналз Инк. | Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция |
US7041870B2 (en) | 2000-11-30 | 2006-05-09 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
ES2372321T3 (es) | 2001-06-20 | 2012-01-18 | Genentech, Inc. | Composiciones y métodos para el diagnóstico y tratamiento de un tumor de pulmón. |
CA2379661A1 (en) | 2002-03-28 | 2003-09-28 | Kursad Turksen | Paracellular drug delivery system |
CA2481507A1 (en) | 2002-04-16 | 2003-10-30 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
AU2003225009A1 (en) * | 2002-04-22 | 2003-11-03 | Dyax Corporation | Antibodies specific for mucin polypeptide |
US20070207142A1 (en) | 2002-05-08 | 2007-09-06 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
JP2006516089A (ja) | 2002-10-02 | 2006-06-22 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
EP3284753B1 (en) | 2002-10-17 | 2019-06-05 | Genmab A/S | Human monoclonal antibodies against cd20 for use in the treatment of multiple sclerosis |
JP2006516192A (ja) | 2002-10-18 | 2006-06-29 | ジェネンテック・インコーポレーテッド | 腫瘍の診断と治療のための組成物と方法 |
AT500651B9 (de) | 2003-05-27 | 2010-04-15 | Altropus Gmbh | Aktiv immunisierender antikörper |
WO2004110363A2 (en) | 2003-05-30 | 2004-12-23 | Centocor, Inc. | Method of inhibiting tumor growth with anti-tissue factor antibodies |
EP2481814A3 (en) | 2003-06-09 | 2012-10-10 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
WO2006033664A1 (en) | 2004-03-08 | 2006-03-30 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
US7431927B2 (en) | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
DE102005025041A1 (de) | 2005-05-30 | 2006-12-07 | Bell Flavors & Fragrances Duft Und Aroma Gmbh | Mittel zur Anwendung in Spülmaschinen sowie Vorrichtung für dessen dosierte Einbringung während der Spül- und Trocknungsphasen |
EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
EP1970384A1 (en) * | 2007-03-14 | 2008-09-17 | Ganymed Pharmaceuticals AG | Monoclonal antibodies for treatment of cancer |
EP2138576A4 (en) | 2007-03-16 | 2011-02-23 | Kyowa Hakko Kirin Co Ltd | ANTI-CLAUDIN-4 ANTIBODY |
EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
WO2009025759A1 (en) * | 2007-08-17 | 2009-02-26 | Progenics Pharmaceuticals (Nevada), Inc. | Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof |
WO2009028663A1 (ja) | 2007-08-30 | 2009-03-05 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-3抗体 |
EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
EP2241578B1 (en) * | 2008-01-11 | 2016-04-20 | The University of Tokyo | Anti-cldn6 antibody |
WO2009126926A2 (en) | 2008-04-11 | 2009-10-15 | Bionovo, Inc. | Anticancer methods employing extracts of gleditsia sinensis lam |
EP2352764B1 (en) | 2008-10-14 | 2018-03-28 | Ablynx N.V. | AMINO ACID SEQUENCES TARGETING HUMAN CD4 and CXCR4, CCR5, TLR4, ALPHAV INTEGRIN, BETA3-INTEGRIN,BETA1-INTEGRIN, HUMAN ALPHA2-INTEGRIN, CD81, SR-BI, CLAUDIN-1, CLAUDIN-6 AND/OR CLAUDIN-9, RESPECTIVELY, AND NEUTRALIZING VIRAL ENTRY |
DE102009026960A1 (de) | 2008-12-18 | 2010-07-01 | Robert Bosch Gmbh | Verfahren zur Steuerung einer Bremsbetätigung eines Hybridfahrzeugs |
JP2010178650A (ja) | 2009-02-04 | 2010-08-19 | Univ Of Tokyo | 固形癌の再発予測のための試験方法および再発予防剤 |
EP2221063A1 (en) | 2009-02-20 | 2010-08-25 | Ganymed Pharmaceuticals AG | Methods and compositions for diagnosis and treatment of cancer |
KR102340685B1 (ko) | 2009-02-20 | 2021-12-17 | 가니메드 파마슈티칼스 게엠베하 | 암의 진단 및 치료를 위한 방법 및 조성물 |
EP2322555A1 (en) * | 2009-11-11 | 2011-05-18 | Ganymed Pharmaceuticals AG | Antibodies specific for claudin 6 (CLDN6) |
BR112012011143B1 (pt) | 2009-11-11 | 2020-05-19 | Ganymed Pharmaceuticals Ag | "anticorpos específicos para claudina 6 (cldn6)". |
WO2011105551A1 (ja) | 2010-02-26 | 2011-09-01 | 国立大学法人大阪大学 | 癌幹細胞の検出方法、及び癌の治療剤または再発予防剤 |
EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
MX341147B (es) | 2011-05-13 | 2016-08-09 | Ganymed Pharmaceuticals Ag | Anticuerpos para el tratamiento del cáncer que expresa cldn6. |
EP2749641B1 (en) | 2011-09-07 | 2021-06-02 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell isolation |
EP2605017A1 (de) | 2011-12-16 | 2013-06-19 | Protagen AG | Markersequenzen für gynäkologisches Malignom und deren Verwendung |
EP2875046B1 (en) | 2012-07-19 | 2020-02-26 | Amgen Inc. | Human btnl3 proteins, nucleic acids, and antibodies and uses thereof |
WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
-
2012
- 2012-04-20 MX MX2013013053A patent/MX341147B/es active IP Right Grant
- 2012-04-20 EP EP12715856.6A patent/EP2707390B1/en active Active
- 2012-04-20 ME MEP-2016-39A patent/ME02369B/me unknown
- 2012-04-20 EP EP18179328.2A patent/EP3421496A1/en active Pending
- 2012-04-20 RS RS20160121A patent/RS54627B1/en unknown
- 2012-04-20 PL PL12715856T patent/PL2707390T3/pl unknown
- 2012-04-20 HU HUE12715856A patent/HUE028603T2/en unknown
- 2012-04-20 UA UAA201708784A patent/UA127584C2/uk unknown
- 2012-04-20 LT LTEP15201110.2T patent/LT3026064T/lt unknown
- 2012-04-20 UA UAA201314474A patent/UA115969C2/uk unknown
- 2012-04-20 NZ NZ741567A patent/NZ741567A/en unknown
- 2012-04-20 KR KR1020207018103A patent/KR102430870B1/ko active IP Right Grant
- 2012-04-20 CA CA2832174A patent/CA2832174C/en active Active
- 2012-04-20 EP EP15201110.2A patent/EP3026064B1/en active Active
- 2012-04-20 DK DK15201110.2T patent/DK3026064T3/en active
- 2012-04-20 CN CN201280022739.1A patent/CN103748112B/zh active Active
- 2012-04-20 KR KR1020137030171A patent/KR102072183B1/ko active IP Right Grant
- 2012-04-20 PL PL15201110T patent/PL3026064T3/pl unknown
- 2012-04-20 CN CN201710009512.8A patent/CN107090043B/zh active Active
- 2012-04-20 ES ES12715856.6T patent/ES2565063T3/es active Active
- 2012-04-20 SI SI201230482T patent/SI2707390T1/sl unknown
- 2012-04-20 NZ NZ724296A patent/NZ724296A/en not_active IP Right Cessation
- 2012-04-20 NZ NZ706004A patent/NZ706004A/en unknown
- 2012-04-20 US US14/117,118 patent/US9321842B2/en active Active
- 2012-04-20 SG SG2013070701A patent/SG193551A1/en unknown
- 2012-04-20 DK DK12715856.6T patent/DK2707390T3/en active
- 2012-04-20 RS RS20181513A patent/RS58087B1/sr unknown
- 2012-04-20 SI SI201231496T patent/SI3026064T1/sl unknown
- 2012-04-20 WO PCT/EP2012/001721 patent/WO2012156018A1/en active Application Filing
- 2012-04-20 CN CN201710009470.8A patent/CN107011440B/zh active Active
- 2012-04-20 JP JP2014510679A patent/JP6276176B2/ja active Active
- 2012-04-20 KR KR1020227026991A patent/KR20220116069A/ko active IP Right Grant
- 2012-04-20 RU RU2013155455A patent/RU2676731C2/ru active
- 2012-04-20 BR BR112013029212A patent/BR112013029212B1/pt active IP Right Grant
- 2012-04-20 AU AU2012258087A patent/AU2012258087B2/en active Active
- 2012-05-08 AR ARP120101613A patent/AR086306A1/es active IP Right Grant
-
2013
- 2013-09-20 ZA ZA2013/07102A patent/ZA201307102B/en unknown
- 2013-10-06 IL IL228738A patent/IL228738B/en active IP Right Grant
- 2013-11-08 MX MX2020001224A patent/MX2020001224A/es unknown
- 2013-11-08 MX MX2020011779A patent/MX2020011779A/es unknown
- 2013-11-08 MX MX2020011778A patent/MX2020011778A/es unknown
-
2014
- 2014-08-22 HK HK14108609.0A patent/HK1195320A1/xx unknown
-
2016
- 2016-02-29 HR HRP20160212TT patent/HRP20160212T1/hr unknown
- 2016-03-01 CY CY20161100181T patent/CY1118608T1/el unknown
- 2016-03-04 SM SM201600064T patent/SMT201600064B/xx unknown
- 2016-03-21 US US15/076,536 patent/US10233253B2/en active Active
-
2017
- 2017-07-07 AU AU2017204663A patent/AU2017204663B2/en active Active
-
2018
- 2018-01-11 JP JP2018002528A patent/JP6637083B2/ja active Active
- 2018-07-05 US US16/028,210 patent/US10919974B2/en active Active
- 2018-12-21 CY CY181101393T patent/CY1121085T1/el unknown
-
2019
- 2019-01-03 HR HRP20190014TT patent/HRP20190014T1/hr unknown
- 2019-08-22 AU AU2019219797A patent/AU2019219797B2/en active Active
-
2020
- 2020-12-30 US US17/138,403 patent/US11859008B2/en active Active
-
2021
- 2021-06-28 AR ARP210101787A patent/AR122771A2/es unknown
- 2021-12-03 AU AU2021277764A patent/AU2021277764A1/en active Pending
-
2023
- 2023-04-12 JP JP2023064843A patent/JP2023089133A/ja active Pending
- 2023-11-27 US US18/520,264 patent/US20240101703A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR122771A2 (es) | Anticuerpos para el tratamiento del cáncer, conjugado, composición farmacéutica, ácido nucleico y célula huésped | |
ES2543174T3 (es) | Composición medicinal para el tratamiento y/o la prevención del cáncer | |
AR117658A2 (es) | Anticuerpos anti-fap y métodos de uso | |
CL2018003807A1 (es) | Anticuerpo humanizado aislado que une al cd134 humano; molécula de ácido nucleico aislada; vector que comprende a la misma célula anfitriona que comprende al mismo; uso del anticuerpo para potenciar una respuesta inmune; uso del anticuerpo para el tratamiento del cáncer, una composición farmacéutica que comprende el anticuerpo. (divisional solicitud 201502793) | |
CY1124632T1 (el) | Προϊοντα συζευξης αναλογων cc-1065 και διλειτουργικοι συνδετες | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
CY1119925T1 (el) | Aνti-cd40 αντισωματα, χρησεις και μεθοδοι | |
AR117911A2 (es) | Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
AR102698A1 (es) | Anticuerpos contra cd73 y sus usos | |
AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
CL2013002990A1 (es) | Compuestos derivados de imidazo[5,1-a]isoindol o sus sales, inhibidores de indolamina 2,3-dioxigenasa (ido); composicion farmaceutica, utiles para tratar la inmunosupresion asociada con una enfermedad infecciosa o cancer. | |
PE20161390A1 (es) | Anticuerpos multiespecificos | |
AR075604A1 (es) | Anticuerpos contra un ligando que induce proliferacion (april) | |
CL2012001096A1 (es) | Proteina de enlace a antigeno aislada que enlaza il-23, que comprende al menos tanto una region variable de cadena pesada como de cadena liviana que comprenden cdrs mutadas; acido nucleico, vector y celula hospedera que la codifican; composicion farmaceutica; y su uso para tratar enfermedades asociadas a il-23 en un paciente. | |
PE20141019A1 (es) | Nuevos inmunoconjugados | |
AR095432A1 (es) | Proteínas de unión a antígeno | |
PE20121563A1 (es) | Anticuerpos que se unen especificamente al receptor epha2 | |
ES2620264T3 (es) | Anticuerpos humanizados frente a LIV-1 y el uso de los mismos para tratar el cáncer | |
CO6700829A2 (es) | Moduladores novedosos y métodos de uso | |
MX2013009151A (es) | Inmunoterapia mejorada. | |
ES2675847T3 (es) | Nuevo anticuerpo anti-DR5 | |
AR075504A1 (es) | Moleculas de anticuerpos que tienen especificidad para el ox40 humano | |
CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
AR075882A1 (es) | Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7 |